ZELLUNA IMMUNOTHERAPY AS
Registration number 816823862 · Norway
ZELLUNA IMMUNOTHERAPY AS is an active company registered in Norway, incorporated in 2016 (about 10 years ago). It reports 9 employees. It has 7 directors / officers on record. It was previously known as TCR BIOPHARMA AS.
- Jurisdiction
- Norway
- Incorporated
- 2016-03-01
- Employees
- 9
- Registered address
- Ullernchausséen 64, 0379, OSLO
- Post code
- 0379
- Registry
- Brønnøysund
- Status
- Active
Directors & officers
- AMESTO ACCOUNTHOUSE AS Accountant
- FORVIS MAZARS OUTSOURCING AS Accountant
- ERNST & YOUNG AS Auditor
- Geir Christian Melen Board member
- Namir Jafar Hassan Board member
- Anders Tuv Chairman of the board
- Namir Jafar Hassan Managing director
Former names
TCR BIOPHARMA AS
Shared operator — likely the same administrator
Companies sharing this one's web or mail infrastructure. A lead for further checks — often an accountant or corporate-services provider, not a corporate relationship.
- Zelluna Immunotherapy AS Shared domain zelluna.com · shared by 3
- Zelluna Immunotherapy AS Shared mail operator zelluna-com.mail.protection.outlook.com · shared by 3
- Zelluna ASA Shared domain zelluna.com · shared by 3
- Zelluna ASA Shared mail operator zelluna-com.mail.protection.outlook.com · shared by 3
Companies at the same registered address
- Zelluna Immunotherapy AS
- NORGENOTECH AS
- SRB RADIOPHARMA HOLDING AS
- ADJUTEC PHARMA AS
- ONCOSYNE AS
- HUBRO THERAPEUTICS AS KONKURSBO
Companies with the same directors
- Zelluna ASA
- NEXTERA AS
- TRANSVEGA AS
- TUV CAPITAL AS
- DOMORE DIAGNOSTICS AS
- NERA BIOTECH CONSULTING LTD
- NORDOVO BIOSCIENCES AS
- SRB RADIOPHARMA HOLDING AS
See the KYB reliability score, EU · OFAC · UK · US sanctions and PEP screening, and the full ownership graph for ZELLUNA IMMUNOTHERAPY AS in the app — or pull it programmatically with a free API key.
Source: GLEIF Global LEI Index. Last read from the source on 2026-07-07. Registers change and registers are sometimes wrong. If anything here is out of date or inaccurate, tell us and we will correct it.